CGTLive

6 days ago | cgtlive.com | Silas Inman

Ciltacabtagene autoleucel (cilta-cel; Carvykti) improved progression-free survival (PFS) and overall survival (OS) compared with standard of care (SOC) across all subgroups of patients with relapsed/refractory multiple myeloma, including in those with extramedullary disease (EMD) and regardless of prior lines of therapy, according to a subgroup analyses from the phase 3 CARTITUDE-4 trial (NCT04181827) presented at the 2025 ASCO Annual Meeting.

6 days ago | cgtlive.com | Jamie M. Jacobs |Noah Stansfield

“I think what's really notable about these findings is not just what significant and clinically meaningful improvements we saw in quality of life and some of our other secondary outcomes, but also how engaged caregivers were using this app content.”For patients receiving many cell-based and other advanced therapies, including hematopoietic stem cell transplant (HSCT), the role of the caregiver is of great importance.

1 week ago | cgtlive.com | Silas Inman

KITE-363 elicited responses in nearly all patients with relapsed/refractory large B-cell lymphoma (LBCL) who were treated with the dual CD19 and CD20-directed chimeric antigen receptor (CAR) T-cell therapy, according to data from a phase 1 study (NCT04989803) presented at the 2025 ASCO Annual Meeting. For the single-arm dose escalation study, KITE-363 was administered at 3 dose levels (DL), with the largest dose selected for further study.

1 week ago | cgtlive.com | Noah Stansfield

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field. The patient’s death occurred after an acute systemic infection and was associated with an unexpected SAE of clinical complications related to a capillary leak syndrome.

1 week ago | cgtlive.com | Joseph A Fraietta |Janna C. Minehart |Caroline DiOrio |Noah Stansfield

0:00 – Intro and guest introduction 2:00 – Challenges in predicting toxicities in preclinical models 10:00 – How manufacturing parameter changes can affect toxicity rates 13:06 – Strategies for managing inflammatory toxicities in smaller medical centers 19:52 – Goal of decoupling treatment potency from toxicity 20:44 – Potential for future unknown toxicities in immunotherapies 24:52 – Challenges in defining and identifying immune effector cell-associated HLH-like syndrome (IEC-HS) biomarkers...